ClinicalTrials.gg
Drug

Sunvozertinib clinical trials

Also written DZD9008.

studies test it
20
open now
10
in phase 3
2
first study started
2019

How each study uses sunvozertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sunvozertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
2 Jul 2025 · ZEGFROVY · NDA 219839 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sunvozertinib
8

Development codes

DZD9008
7

In one entry with another drug

Given together, or one or the other

sunvozertinib in combination with Anlotinib
2

Studies by the year they started

20 studies that test it; most in 2024 (6)

Studies that test sunvozertinib, by start year
YearStudies
20191
20215
20222
20233
20246
20253

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
13
Phase 3
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 9

Dizal Pharmaceuticals (10) · Hunan Province Tumor Hospital (2) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Shanghai Zhongshan Hospital (1) · Peking Union Medical College Hospital (1) · Sichuan University (1) · Sun Yat-sen University (1) · Fudan University (1)

Often tested with

Tested in the same studies.

Anlotinib (3) · Golidocitinib (1) · Antineoplastic Agents (1) · Crizotinib (1) · Pralsetinib (1) · Larotrectinib (1) · Savolitinib (1) · Pyrotinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test sunvozertinib.

Studies

Open first, then newest update. How each study uses sunvozertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 20

Given beside what is tested · 2 — sunvozertinib is usual care or a partner of the new treatment

Codes

What other systems call sunvozertinib · ClinicalTrials.gg INT002120

  • MeSH (NLM) C000731668sunvozertinibOne source NLM
  • UNII (FDA) L1Q2K5JYO8SUNVOZERTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q130051139sunvozertinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C167205SunvozertinibOne source FDA
  • DrugBank DB18925One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.